Abstract. Congenital mesoblastic nephroma (CMN) is a mesenchymal renal tumor. The aim of the present study was to review the clinical characteristics and outcome of CMN in infants. A retrospective file review was conducted of eight cases of CMN treated at the Children's Hospital of Fudan University between 2004 and 2012. Ultrasound and computerized tomography scans had been performed on all eight patients. Two cases presented with a solid tumor and exhibited pathological features consistent with those of classic CMN, five cases exhibited cystic, hemorrhagic and necrotic characteristics, with calcification and pathology consistent with the cellular variant of CMN and one case presented with a solid tumor, which exhibited pathological features consistent with cellular CMN. Histology confirmed classic CMN in two patients and cellular CMN in six patients. For surgical intervention, four cases had radical nephrectomy, one case had a half nephrectomy and three cases had tumor enucleation performed. Two cases had received pre-operative chemotherapy, but exhibited no response, and three cases received post-operative chemotherapy. Two patients were lost to follow-up, but the remaining six patients survived to the end of follow-up without further complications. The mean follow-up time was 24.6 months. In conclusion, the differential diagnosis between CMN and Wilms' tumor is critical. Imaging characteristics are partially correlated with pathological characteristics. Surgery is the main treatment for CMN, but pre-operative chemotherapy is not particularly effective. The efficacy of post-operative chemotherapy requires further investigation, but the prognosis is positive.

Introduction

Congenital mesoblastic nephroma (CMN) is a mesenchymal renal tumor that was distinguished from Wilms' tumor (WT) in 1967 (1). CMN is the most frequent type of renal tumor in the neonatal and early infantile period, comprising 3-10% of all childhood renal tumors. CMN has three pathological variants: Classic CMN, the more aggressive cellular CMN and the mixed variant. Classic CMN has a good overall prognosis, but cellular CMN is associated with the potential for malignancy, and is capable of recurrence and metastasis (2). However, surgical resection with nephrectomy is considered an adequate therapy for all subtypes, provided that a complete resection is achieved.

van den Heuvel-Eibrink et al (3) reported a five-year event-free survival (EFS) rate of 94% and an overall survival (OS) rate of 96% in infants with CMN. Furtwaengler et al (4) reported that patients with the cellular subtype had EFS and OS rates of 85 and 90%, respectively; no recurrences or fatalities were reported among the patients with classic CMN. In the present study, to examine disease features, imaging characteristics, treatment approach and outcome for children with CMN, a retrospective analysis of eight cases of CMN treated between April 2004 and August 2012 at the Children's Hospital of Fudan University (Shanghai, China) was performed.

Patients and methods

Eight patients with a diagnosis of CMN attending the Children's Hospital of Fudan University between 2004 and 2012 were identified, and the clinical charts were reviewed retrospectively to document presentation, treatment and follow-up, subsequent to obtaining approval from the local research ethics committee of the hospital and written informed consent from the parents of each patient.

Results

Clinical analysis. The participants included six male and two female patients (Table I). The ages of the patients at diagnosis ranged between five hours and 17 months, with a mean age of 4.4 months. The study included four cases that were diagnosed in the neonatal period. The tumor arose from the left kidney in three patients and from the right kidney in five. Three cases were admitted to the hospital for hematuria, two cases for prenatal diagnosis by ultrasound (US), one case for progressive abdominal distension and two cases for an abdominal mass. The amniotic fluid in all eight cases was normal, but one case exhibited hypertension.
Imaging analysis. US revealed that three cases were solid tumors, and five had heterogeneity accompanied by cystic areas and either hypoechoic necrosis or hyperechoic calcification. Computerized tomography (CT) revealed similar results, with three cases suggesting the presence of a predominantly solid mass and five patients exhibiting cysts, hemorrhagic, necrosis or calcification components. Of the five cases that had emission CT performed (patients 1,3,5,6 and 8), four exhibited no abnormalities. Case 1 exhibited lesions in the right tibia, which may suggest bone metastases. Combining imaging characteristics and clinical symptoms, seven cases were initially diagnosed as WT and one as neuroblastoma.

Pathological analysis. All eight patients received surgical treatment: Four cases underwent radical nephrectomy, one case underwent a half nephrectomy and three cases received tumor enucleation. Four of these cases were also treated by lymph node dissection. The pathological findings were as follows: Two cases were diagnosed with classic CMN and six cases with cellular CMN. On gross examination, the CMNs appeared as soft, fleshy tumors, ranging in size between 3x2x2 cm and 20x16x14 cm, with an average volume of 1,310 cm³, and the maximum diameter was 20 cm. The cellular CMNs were commonly multicystic with areas of gross hemorrhage, clear fluid accumulations or calcification. Histologically, in classic CMN, uniform fascicles of spindled cells resembling fibroblasts or myofibroblasts are observed, which was also observed in the present study. The mitotic rate is low with relatively abundant collagen. In cellular CMN, fusiform or ovoid high densities of spindle cells impart a sarcomatous appearance. An increased number of mitotic cells are also observed and the cells are more densely arranged (4-6).

Seven of the eight cases were also examined using immuno-histochemical staining (Table II): Positive vimentin (VIM) and Ki-67 antigen (Ki-67) staining was observed in seven and six cases, respectively; negativity for CD34 antigen (CD34), epithelial membrane antigen (EMA), CKpan (CK), Desmin (DES) and smooth muscle actin (SMA) was observed in six, five, five, four and three cases, respectively.

Discussion

CMN is the most common type of renal tumor in newborns and infants under three months of age, and 90% of cases occur in patients under one year old. The main symptoms at the time of diagnosis are the development of an abdominal mass and hematuria. Increasing numbers of CMN patients are diagnosed in the prenatal period by US (8), including two cases in the present study. The reported male to female ratio is ~1.5:1 and the right kidney to left kidney ratio is ~1:1 (9). In the patient group in the present study, the male to female ratio was 3:1 and the right kidney to left kidney ratio was 5:3. Seven cases were diagnosed in patients under one year old and four were diagnosed in the neonatal period. Despite the small number of cases, the features were consistent with the epidemiological characteristics reported in previous studies.

Bayindir et al (10) observed that hypertension was present in 70% of CMN patients and the mother is usually reported to have polyhydramnios (11,12). However, only one case in the present study exhibited hypertension and the amniotic fluid levels were normal in all cases. Hypertension and polyhydramnios were uncommon as disease-associated symptoms.

Table I. Clinical features and pathological findings in eight patients with CMN.

| Patient no. | Gender | Age | Location | Reason for admission | Subtype | Initial diagnosis |
|------------|--------|-----|----------|----------------------|---------|------------------|
| 1          | Female | 17 m| Left kidney | Abdominal mass | Classic stage IV<sup>a</sup> | WT |
| 2          | Male   | 5 h | Left kidney | Prenatal diagnosis | Classic stage I | WT |
| 3          | Male   | 44 d| Left kidney | Abdominal distension | Cellular stage I | Neuroblastoma |
| 3<sup>b</sup> | Male   | 9 m | Left kidney | Abdominal mass | Cellular stage II | CMN |
| 4          | Male   | 9 m | Right kidney | Hematuresis | Cellular stage I | WT |
| 5          | Male   | 17 d| Right kidney | Abdominal mass | Cellular stage I | WT |
| 6          | Male   | 13 d| Right kidney | Hematuresis | Cellular stage I | WT |
| 7          | Female | 11 h| Right kidney | Prenatal diagnosis | Cellular stage I | WT |
| 8          | Male   | 7 m | Right kidney | Hematuresis | Cellular stage I | WT |

<sup>a</sup>Possible subtype; <sup>b</sup>Recurrence of case no. 3. CMN, congenital mesoblastic nephroma; h, hours; d, days; m, months; WT, Wilms’ tumor.
A differential diagnosis between CMN and WT is critical to develop the most effective therapeutic approach. The examination of clinical symptoms and imaging characteristics shows that WT is similar to CMN, particularly the cellular variant, but fewer than 2% patients with WT present at under three months of age. Tumors with congenital syndromes or anomalies, and the presence of bilateral tumors are clearly more suggestive of WT. Electron microscopy provides detailed morphological information that may be applied to achieve the required differential diagnosis. In total, ~24% CMN is reported to be the classic type; cellular variants account for ~66% and mixed variants for ~10% (13). CMN is generally a benign tumor, but occasionally local recurrence occurs and distant metastases have been reported in cellular CMN, with the main site of metastasis the lung. Tumors in the brain, liver, heart, bone and other tissues are extremely rare (14-18).

In the present study, classical CMN accounted for 25% of all cases, cellular CMN accounted for 75% of all cases and no mixed type was observed. Immunohistochemistry aids in performing differential diagnosis; CMN generally exhibits the following results: VIM (+), Ki-67 (+), CD34 (-), EMA (-), CK (-), DES (-) and SMA (-) (4); and this pattern was detected in four out of the seven cases analyzed. Regarding imaging characteristics, Chaudry et al (19) reported that the cystic masses, and intratumoral hemorrhagic and necrotic changes commonly appear in cellular CMN. In the present study, if either the US or CT indicated the presence of a solid mass, the tumor was often diagnosed as classic CMN, but if either examination indicated cysts, hemorrhagic necrosis or calcification, the tumor was commonly classified as cellular CMN. In addition, Anderson et al (20) analyzed the tumors from 15 CMN cases using reverse transcription polymerase chain reaction and found the existence of the ETV6-NTRK3 fusion gene, which is caused by the (12; 15) (p13; q25) translocation. The three positive cases were all cellular CMN, but the negative cases were of the classic and mixed types, suggesting that ETV6-NTRK3 gene expression levels may be associated with the CMN pathological type. Shared histopathology and translocation gene fusion results support the concept of cellular CMN as the renal form of infantile fibrosarcoma (IFS), while classic CMN is equivalent to infantile fibromatosis (19).

A significant degree of regression in CMN without any treatment, possibly correlated with t (12; 15) (p13; q25) gene translocations, was observed by Whittle et al (22), but

| Table II. Immunohistochemical staining in CMN patients. |
|-------------------------------------------|
| Patient no. | VIM | Ki-67 | CD34 | EMA | CK | DES | SMA |
|--------------|-----|-------|------|-----|----|-----|-----|
| 1            | +   | -     | +    | /   | +  | -   | +   |
| 2            | +   | +     | -    | -   | -  | -   | /   |
| 3            | /   | /     | /    | /   | /  | /   | /   |
| 4            | +   | +     | -    | -   | -  | -   | -   |
| 5            | +   | +     | -    | -   | -  | -   | +   |
| 6            | +   | +     | -    | -   | -  | -   | /   |
| 7            | +   | +     | -    | -   | -  | -   | -   |
| 8            | +   | +     | -    | +   | +  | -   | /   |
| Total        | 7+  | 6+    | 1-   | 6-,1+| 5-,1+| 5-,2+| 4-   | 3-,2+|

CMN, congenital mesoblastic nephroma; VIM, vimentin; Ki-67, Ki-67 antigen; CD34, CD34 antigen; EMA, epithelial membrane antigen; CK, CKpan; DES, Desmin; SMA, smooth muscle actin; +, positive staining; -, negative staining; /, not examined.

| Table III. Treatment and follow-up of eight CMN cases. |
|-------------------------------------------|
| Patient no. | Pre  | Post | Surgery          | Lymph node dissection | Margin | Follow-up time (months) |
|--------------|------|------|------------------|-----------------------|--------|------------------------|
| 1            | EE-4A| EE-4A| Nephrectomy      | Yes                   | (-)    | Lost                   |
| 2            | /    | /    | Tumor enucleation| No                    | (-)    | Lost                   |
| 3            | /    | /    | Tumor enucleation| Yes                   | (-)    | 20                     |
| 3a           | DD-4A| DD-4A| Tumor resection  | Yes                   | (-)    | 48                     |
| 4            | /    | /    | Half nephrectomy | No                    | (-)    | 28                     |
| 5            | /    | /    | Nephrectomy      | Yes                   | (-)    | 27                     |
| 6            | /    | /    | Tumor enucleation| No                    | (-)    | 22                     |
| 7            | /    | /    | Nephrectomy      | No                    | (-)    | 19                     |
| 8            | /    | EE-4A| Nephrectomy      | Yes                   | (-)    | 16                     |

4aRecurrence of case no. 3. CMN, congenital mesoblastic nephroma; pre, preoperative chemotherapy; post, postoperative chemotherapy; EE-4A, dactinomycin and vincristine; DD-4A, dactinomycin, vincristine and doxorubicin; /, not examined; (-), negative.
additional evidence is required for further support. Complete surgical resection is the primary treatment for CMN. The local recurrence rate of CMN is ~5%, commonly due to an incomplete resection (12). England et al (9) observed a group of 47 patients with CMN who had been treated by whole nephrectomy and exhibited no recurrence. In the group in the present study, four cases had a whole renal resection, one case received a half nephrectomy and three cases underwent tumor enucleation, with four cases receiving additional lymph node dissection. Case 3 had tumor resection with peritoneal lymph node dissection performed and had a recurrence after eight months, possibly due to the presence of residual tumor tissue. Considering the potential for recurrence, radical nephrectomy is the preferred treatment for CMN.

Case 1, with classical CMN, was initially diagnosed as WT with the possibility of metastases and received an EE-4A treatment regimen. Case 3, with cellular CMN and tumor recurrence after eight months, received a treatment regimen of DD-4A prior to the second surgical treatment. These two cases exhibited no marked response to the pre-operative chemotherapy; the patients received post-operative chemotherapy with the same respective regimens. Case 8, with cellular CMN, received an EE-4A treatment regimen following radical nephrectomy. The decision to administer adjuvant chemotherapy remains controversial and the general preferred treatment for stage I renal tumors is immediate surgery. The likelihood of a renal tumor being non-malignant is markedly reduced with presentation beyond the age of three months (9). Therefore, although surgical risk factors may be perceived, as determined by the condition or tumor characteristics, pre-operative chemotherapy, possibly preceded by biopsy to confirm pathological diagnosis, requires serious consideration.

Pre-operative chemotherapy, with an appropriate dose reduction, has been well-tolerated by young infants (22). If the WT chemotherapeutic regimens are unsuccessful, considering the histological and genetic similarities between CMN and IFS, a sarcoma chemotherapy regimen may be attempted (18). In the patients in the present study, a nine-month old with cellular CMN recurrence and a 17-month old with classic CMN received a WT pre-operative chemotherapy regimen; renal tumors from neither patient had significantly shrunken. Previously, other CMN cases with failed chemotherapy regimens have been reported (7,23). As CMN patients are commonly diagnosed in the first three months of life and are not always sensitive to chemotherapy, routine pre-operative chemotherapy is not recommended and radical surgery is the first choice. If the patient cannot receive surgery, either the WT or sarcoma chemotherapy regimen is accepted as viable treatment (24,25).

Patients older than three months with stage III cellular CMN have been previously found to suffer from a greater recurrence rate than that of younger patients (7). Those with incomplete resection of the tumor, diagnosed by positive lymph node biopsy, and patients with stage III cellular variants, require adjuvant treatment. In the present study, three cases older than three months had stage I-II cellular CMN; two of these patients received post-operative chemotherapy and, upon follow-up, none of the three patients have presented with recurrence. In general, the application of post-operative chemotherapy requires further follow-up observation. Due to complications from chemotherapy, post-operative chemotherapy is not currently recommended for the treatment of the stage I-II cellular variant of CMN; however, a close follow-up of the patients should be conducted. The overall prognosis for CMN is good, but is affected by age and maturity. All six cases in the present study that were not lost to follow-up survived tumor-free.

In conclusion, CMN requires a differential diagnosis from WT and imaging characteristics are partially correlated with pathological characteristics. The US and CT scans revealed cellular CMN as an area with cystic, hemorrhagic and necrotic characteristics and calcification. By contrast, classic CMN was commonly observed as a solid mass. Surgery is the primary treatment, although for patients who cannot receive surgery or patients older than three months with cellular CMN, pre-operative chemotherapy is an option, although the efficacy is uncertain. Patients who have stage III cellular CMN and are aged three months or older at diagnosis may receive post-operative chemotherapy, although the efficacy of this regimen requires further investigation. For patients with stage I-II cellular CMN, chemotherapy is not recommended and the overall prognosis of CMN is fairly good.

Acknowledgements

The current study was supported by the National Natural Science Foundation of China (grant no. 81071903).

References

1. Bolande RP, Brough AJ and Izant JR Jr: Congenital mesoblastic nephroma of infancy. A report of eight cases and the relationship to Wilms' tumor. Pediatrics 40: 272-278, 1967.
2. Glick RD, Hicks MJ, Nuchtern JG, et al: Renal tumors in infants less than 6 months of age. J Pediatr Surg 39: 522-525, 2004.
3. van den Heuvel-Eibrink MM, Grundy P, Graf N, et al: Characteristics and survival of 750 children diagnosed with a renal tumor in the first seven months of life: A collaborative study by the SIOP/GPOH/SFOP, NWTSG, and UKCCSG Wilms tumor study groups. Pediatr Blood Cancer 50: 1130-1134, 2008.
4. Bisceglia M, Carosi I, Vairo M, Zaffarano L, Bisceglia M and Creti G: Congenital mesoblastic nephroma: report of a Case with review of the most significant literature. Pathol Res Pract 196: 199-204, 2000.
5. Gruver AM, Hansel DE, Luthringer DJ and MacLennan GT: Congenital mesoblastic nephroma. J Urol 183: 1188-1189, 2010.
6. Chaudry G, Perez-Atayde AR, Negan BY, Gundogan M and Daneman A: Imaging of congenital mesoblastic nephroma with pathological correlation. Pediatr Radiol 39: 1080-1086, 2009.
7. Furtwaengler R, Reinhard H, Leuschner I, et al; Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) Nephroblastoma Study Group: Mesoblastic nephroma - a report from the Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH). Cancer 106: 2275-2283, 2006.
8. Montaruli E and Fouquet V: Prenatal diagnosis of congenital mesoblastic nephroma, Fetal Diagn Ther 33: 79-80, 2012.
9. Englund RJ, Haidar N and Vujanic GM, et al: Mesoblastic nephroma: A report of the United Kingdom children's cancer and leukaemia group (CCLG). Pediatr Blood Cancer 56: 744-748, 2011.
10. Bayindir P, Guillerman RP, Hicks MJ and Chintagumpala MM: Cellular mesoblastic nephroma (infantile renal fibrosarcoma): institutional review of the clinical, diagnostic, imaging, and pathologic features of a distinctive neoplasm of infancy. Pediatr Radiol 39: 1066-1074, 2009.
11. Al-Turkistani HK: Congenital mesoblastic nephroma: a case report. J Family Community Med 15: 91-93, 2008.
12. Daskas N, Argyropoulou M, Pavlou M and Andronikou S: Congenital mesoblastic nephroma associated with polyhydramnios and hypercalcaemia. Pediatr Nephrol 17: 187-189, 2002.
13. Gruver AM, Hansel DE, Luthringer DJ and MacLennan GT: Congenital mesoblastic nephroma. J Urol 183: 1188-1189, 2010.
14. Heidelberger KP, Ritchey ML, Dauser RC, McKeever PE and Beckwith JB: Congenital mesoblastic nephroma metastatic to the brain. Cancer 72: 2499-2502, 1993.
15. Steinfeld AD, Crowley CA, O'Shea PA and Tefft M: Recurrent and metastatic mesoblastic nephroma in infancy. J Clin Oncol 2: 956-960, 1984.
16. Gonzalez-Crussi F, Sotelo-Avila C and Kidd JM: Malignant mesenchymal nephroma of infancy: report of a case with pulmonary metastases. Am J Surg Pathol 4: 185-190, 1980.
17. Schlesinger AE, Rosenfield NS, Castle VP and Jasty R: Congenital mesoblastic nephroma metastatic to the brain: a report of two cases. Pediatr Radiol 25 (Suppl 1): S73-S75, 1995.
18. Patel Y, Mitchell CD and Hitchcock RJ: Use of sarcoma-based chemotherapy in a case of congenital mesoblastic nephroma with liver metastases. Urology 61: 1260, 2003.
19. Chaudry G, Perez-Atayde AR, Ngan BY, Gundogan M and Daneman A: Imaging of congenital mesoblastic nephroma with pathological correlation. Pediatr Radiol 39: 1080-1086, 2009.
20. Anderson J, Gibson S and Sebire NJ: Expression of ETV6-NTRK in classical, cellular and mixed subtypes of congenital mesoblastic nephroma. Histopathology 48: 748-753, 2006.
21. Rubin BP, Chen CJ, Morgan TW, et al: Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am J Pathol 153: 1451-1458, 1998.
22. Whittle S, Gosain A, Brown PY, et al: Regression of a congenital mesoblastic nephroma. Pediatr Blood Cancer 55: 364-368, 2010.
23. Jones VS and Cohen RC: Atypical congenital mesoblastic nephroma presenting in the perinatal period. Pediatr Surg Int 23: 205-209, 2007.
24. Loeb DM, Hill DA and Dome JS: Complete response of recurrent cellular congenital mesoblastic nephroma to chemotherapy. J Pediatr Hematol Oncol 24: 478-481, 2002.
25. McCallon E, Sorensen PH, Davis JH, Rogers PC and Schultz KR: Non-resectable congenital tumors with the ETV6-NTRK3 gene fusion are highly responsive to chemotherapy. Med Pediatr Oncol 40: 288-292, 2003.
26. Chan KL, Chan KW, Lee CW and Saing H: Preoperative chemotherapy for mesoblastic nephroma. Med Pediatr Oncol 24: 271-273, 1995.